BioJiva

Executive Summary

BioJiva is a clinical-stage pharmaceutical company developing first-in-class therapeutics targeting lipid peroxidation (LPO), a key driver of degenerative diseases. The company's proprietary platform creates oxidation-resistant armored polyunsaturated fatty acids (PUFAs) designed to mitigate LPO-mediated cellular damage. BioJiva's lead candidate is currently in Phase 1 clinical trials, evaluating safety and tolerability in patients with diseases associated with oxidative stress. The approach addresses a significant unmet need, as no approved therapies directly inhibit LPO. With a strong scientific foundation and early clinical progress, BioJiva is positioned to advance its pipeline toward proof-of-concept studies. The company's technology has potential applications across multiple degenerative conditions, including neurological, cardiovascular, and metabolic diseases. As a private entity, BioJiva's financial details are undisclosed, but the Phase 1 milestone suggests ongoing investor support.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 safety and tolerability data readout60% success
• Q2 2027Initiation of Phase 2 proof-of-concept trial40% success
• Q3 2026Potential partnership or licensing deal for platform technology30% success